Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA

Panelists discuss how patient selection criteria for second-line chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma encompass both clinical eligibility guidelines and practical considerations, including geographical and financial factors.

Panelists discuss how institutional challenges around chimeric antigen receptor T-cell therapy slot availability and waiting list management influence treatment sequencing decisions and affect subsequent therapy choices in earlier treatment lines for multiple myeloma.

Panelists discuss how emerging data on chimeric antigen receptor T-cell therapies ciltacabtagene autoleucel and idecabtagene vicleucel for earlier treatment lines in relapsed/refractory multiple myeloma influence institutional decision-making factors for their implementation.